Patent · US Active

Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates

US7759070B2 · kind B2 · utility

1Cited by

0References

24Claims

0Family size

Assignee

National Research Council of Canada · CA

Inventors

Andrew Cox · Ottawa, CA
James Clare Richards · Ottawa, CA

Key dates

Filing date	May 16, 2005
Grant date	Jul 20, 2010
Priority date	—
Expiry date	Jun 29, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12R2001/01
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A conserved inner-core oligosaccharide epitope expressed on the lipopolysaccharide (LPS) of a range of disease causing pathogenic bacterial isolates, including Actinobacillus pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) and Pasteurella multocida (Pm), is disclosed. Construction of a mutant bacterial strain exclusively expressing the conserved inner core OS epitope as a terminally exposed structure has allowed the identification, production and isolation of an inner core LPS which is common to all three organisms. Further provided are associated vaccines, antibodies raised against the conserved LPS inner core and glycoconjugates comprising the LPS inner core linked to an immunogenic carrier.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.